Can Semaglutide Help with Alcohol Cravings?

Why Semaglutide Is Being Discussed in Addiction Medicine

Semaglutide is best known as the active ingredient in medications such as Ozempic and Wegovy. Similar medications, including tirzepatide products such as Mounjaro and Zepbound, are often discussed together as GLP-1 or incretin-based medications.

These medications were developed for diabetes, weight management, and related metabolic conditions. But many patients and clinicians have noticed something interesting: some people taking GLP-1 medications report less interest in alcohol, fewer cravings, or less “reward” from drinking.

That observation has led researchers to ask whether medications that affect appetite, fullness, and reward pathways might also have a role in alcohol use disorder or other addictive behaviors.

Appetite, Reward, and Craving

GLP-1 medications do more than slow digestion or help people feel full sooner. GLP-1 receptors are also present in parts of the brain involved in motivation, reward, and craving.

That matters because alcohol use disorder is not simply a matter of willpower. Alcohol can affect reward pathways, habit formation, stress response, sleep, mood, and other brain systems. Over time, many people find themselves drinking more than they intended, thinking about alcohol more than they want to, or struggling to stop even when alcohol is causing problems.

The scientific question is whether GLP-1 medications may reduce some of that drive toward alcohol in the same general way they may reduce appetite or “food noise” for some patients.

What the Research Shows So Far

The research is promising, but still early.

A 2025 randomized clinical trial published in JAMA Psychiatry studied once-weekly semaglutide in adults with alcohol use disorder. The study found reductions in alcohol craving and some drinking-related outcomes compared with placebo. However, it was a small phase 2 trial with 48 randomized participants, so the authors concluded that the results support larger clinical trials rather than immediate routine use.

Other studies have also suggested a possible connection. For example, a 2025 JAMA Psychiatry observational study found that semaglutide and liraglutide use among patients with alcohol use disorder and obesity or type 2 diabetes was associated with lower risk of alcohol-related hospitalization. Observational studies like this are useful, but they cannot prove cause and effect in the same way a randomized trial can.

The best summary is this: GLP-1 medications may eventually become part of addiction medicine, but the evidence is not yet strong enough to treat semaglutide as a standard alcohol use disorder medication.

Proven Treatments Still Matter

Semaglutide is not currently FDA-approved for alcohol use disorder. The FDA-approved medications for alcohol use disorder remain disulfiram, naltrexone, and acamprosate. These are often combined with counseling, recovery support, lifestyle changes, and individualized medical care.

Naltrexone, including the monthly injection Vivitrol, can help reduce cravings and the rewarding effect of alcohol. Acamprosate may help support abstinence after someone has stopped drinking. Disulfiram can be useful in selected situations when its risks, benefits, and purpose are clearly understood.

These medications are not perfect, and they are not the right fit for every patient. But they are established tools, and they are often underused.

A Careful Approach to GLP-1 Medications

Patients should be cautious about any clinic, advertisement, or online service that presents semaglutide as a simple cure for alcohol use disorder or addiction.

This is especially important with compounded or non-FDA-approved GLP-1 products. The FDA has warned about dosing errors with compounded injectable semaglutide, including cases where patients required medical attention or hospitalization. Reported adverse events included nausea, vomiting, abdominal pain, dehydration, pancreatitis, gallstones, and fainting.

For patients already taking Ozempic, Wegovy, Mounjaro, Zepbound, or another GLP-1 medication, changes in alcohol craving are worth discussing with a clinician. But that does not mean the medication is enough by itself, and it does not replace medical evaluation for alcohol use disorder, withdrawal risk, or other treatment options.

How Shoreline Thinks About This

At Shoreline, we see semaglutide and related medications as an important area to follow, not as a replacement for established addiction treatment.

The right question is not simply, “Does semaglutide help with alcohol?” The better question is, “What does this person need to reduce risk, feel better, and move toward the life they want?”

For some patients, that may mean naltrexone, Vivitrol, acamprosate, or other medication treatment. For others, it may mean help with withdrawal, sleep, anxiety, therapy referrals, recovery support, or a plan to cut back safely. In the future, GLP-1 medications may become part of that conversation for selected patients, but the evidence is still developing.

Addiction medicine should be curious about new science without getting ahead of it.